Cargando…
PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429078/ http://dx.doi.org/10.1097/01.HS9.0000851152.49123.64 |
| _version_ | 1784779321357893632 |
|---|---|
| author | Li, S. Wen, S.-J. Ma, J. |
| author_facet | Li, S. Wen, S.-J. Ma, J. |
| author_sort | Li, S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429078 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94290782022-08-31 PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA Li, S. Wen, S.-J. Ma, J. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429078/ http://dx.doi.org/10.1097/01.HS9.0000851152.49123.64 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Li, S. Wen, S.-J. Ma, J. PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA |
| title | PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA |
| title_full | PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA |
| title_fullStr | PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA |
| title_full_unstemmed | PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA |
| title_short | PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA |
| title_sort | pb2080: efficacy and safety of bendamustine-based regimens as first-line treatment for indolent b-cell non-hodgkin lymphoma: a prospective, multicenter, real-world study in china |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429078/ http://dx.doi.org/10.1097/01.HS9.0000851152.49123.64 |
| work_keys_str_mv | AT lis pb2080efficacyandsafetyofbendamustinebasedregimensasfirstlinetreatmentforindolentbcellnonhodgkinlymphomaaprospectivemulticenterrealworldstudyinchina AT wensj pb2080efficacyandsafetyofbendamustinebasedregimensasfirstlinetreatmentforindolentbcellnonhodgkinlymphomaaprospectivemulticenterrealworldstudyinchina AT maj pb2080efficacyandsafetyofbendamustinebasedregimensasfirstlinetreatmentforindolentbcellnonhodgkinlymphomaaprospectivemulticenterrealworldstudyinchina |